Endometrial Cancer Clinical Trials in Boston, Massachusetts
31 recruitingBoston, Massachusetts
Showing 1–20 of 31 trials
Recruiting
Phase 1
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ovarian CancerOvarian CarcinomaAdvanced Solid Tumor+8 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 1Phase 2
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Breast CancerOvarian CancerCervical Cancer+5 more
Terremoto Biosciences Inc.205 enrolled15 locationsNCT07109726
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Gastric CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Phase 1Phase 2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ovarian CancerEndometrial CancerLung Adenocarcinoma
AstraZeneca506 enrolled60 locationsNCT05797168
Recruiting
Not Applicable
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
Endometrial CancerLynch SyndromeEarly Detection of Cancer+1 more
Jessica D. St. Laurent, MD25 enrolled1 locationNCT07220239
Recruiting
Not Applicable
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Ovarian CancerEndometrial CancerOvarian Carcinoma+4 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT04997096
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Breast CancerBiliary Tract CancerOvarian Cancer+1 more
NextCure, Inc.145 enrolled14 locationsNCT06774963
Recruiting
Phase 1Phase 2
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Ovarian CancerEndometrial CancerPrimary Peritoneal Cancer+1 more
Regeneron Pharmaceuticals612 enrolled24 locationsNCT04590326
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+4 more
ModeX Therapeutics, An OPKO Health Company115 enrolled6 locationsNCT06239194
Recruiting
Phase 2
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Ovarian CancerEndometrial Cancer
Dana-Farber Cancer Institute180 enrolled3 locationsNCT03675893
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Not Applicable
Comprehensive Outcomes for After Cancer Health
Breast CancerMetastatic Breast CancerGastric Cancer+8 more
Pack Health625 enrolled7 locationsNCT05349227